---
title: "Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Guidelines questions"
description: "Guidelines questions on Xarelto (rivaroxaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Xarelto and the 2023 AF guideline: are DOACs recommended over warfarin? Xarelto in severe obesity: what does the 2023 AF guideline say about DOACs? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/guidelines"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Guidelines questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)

Questions that apply to every indication of Xarelto are on [Xarelto (rivaroxaban), all indications](https://www.evicenter.com/medical-information/xarelto).

## Guidelines

<a id="xarelto-guideline-doac"></a>

### Xarelto and the 2023 AF guideline: are DOACs recommended over warfarin?

> “For patients with AF and an estimated annual thromboembolic risk of ≥2%/year  
> (eg, CHA2DS2-VASc score of ≥2 in men and ≥3 in women), anticoagulation is recommended to 
> prevent stroke and systemic thromboembolism.”

Source: [XARELTO: cp-453410v3-XARELTO-Flashcard-04.28.pdf, page 1, captured 2026-11-13](https://www.xareltohcp.com/docs/cp-453410v3-XARELTO-Flashcard-04.28.pdf#page=1)

> “In patients with AF who do not have a history of moderate to severe rheumatic mitral stenosis or 
> a mechanical heart valve, and who are candidates for anticoagulation, DOACs are recommended 
> over warfarin to reduce the risk of mortality, stroke, systemic embolism, and ICH.”

Source: [XARELTO: cp-453410v3-XARELTO-Flashcard-04.28.pdf, page 1, captured 2026-11-13](https://www.xareltohcp.com/docs/cp-453410v3-XARELTO-Flashcard-04.28.pdf#page=1)

Note: In the flashcard, both recommendations are Class I (Strong), Level of Evidence A (High-quality). These are class recommendations of the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline for direct oral anticoagulants (DOACs), as reproduced in the guideline flashcard that the Xarelto HCP site links; they do not name XARELTO.

<a id="xarelto-guideline-obesity"></a>

### Xarelto in severe obesity: what does the 2023 AF guideline say about DOACs?

> “In patients with AF and class III obesity (BMI ≥40 kg/m<sup>2</sup>), DOACs are reasonable  
> to choose over warfarin for stroke risk reduction.”

Source: [XARELTO: cp-453410v3-XARELTO-Flashcard-04.28.pdf, page 2, captured 2026-11-13](https://www.xareltohcp.com/docs/cp-453410v3-XARELTO-Flashcard-04.28.pdf#page=2)

> “In patients with AF who have undergone bariatric surgery, warfarin may be 
> reasonable to choose over DOACs for stroke risk reduction in view of concerns 
> about DOAC drug absorption.”

Source: [XARELTO: cp-453410v3-XARELTO-Flashcard-04.28.pdf, page 2, captured 2026-11-13](https://www.xareltohcp.com/docs/cp-453410v3-XARELTO-Flashcard-04.28.pdf#page=2)

> “*Class III obesity is defined as BMI ≥40 kg/m².”

Source: [XARELTO: cp-453410v3-XARELTO-Flashcard-04.28.pdf, page 2, captured 2026-11-13](https://www.xareltohcp.com/docs/cp-453410v3-XARELTO-Flashcard-04.28.pdf#page=2)

Note: In the flashcard, the first recommendation is Class 2a (Moderate), Level of Evidence B-NR, and the second Class 2b (Weak), Level of Evidence C-LD. These are class recommendations of the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline for direct oral anticoagulants (DOACs), as reproduced in the guideline flashcard that the Xarelto HCP site links; they do not name XARELTO.

## Related pages
- [Medical information: Xarelto (rivaroxaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/access-and-coverage)
